dsp 4 has been researched along with levodopa in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kondo, T; Narabayashi, H; Nishi, K | 2 |
| Gibson, CJ | 1 |
| Hallman, H; Jonsson, G | 1 |
| Schmidt, WJ; Srinivasan, J | 1 |
| Archer, T; Fredriksson, A | 2 |
| Barbanoj, M; Kulisevsky, J; Pérez, V; Rodríguez-Alvarez, J; Rubio, A; Sosti, V | 1 |
| Barbanoj, M; Gich, I; Kulisevsky, J; Pérez, V; Rodríguez-Alvarez, J; Rubio, A; Sosti, V | 1 |
| Aguilar, E; Barbanoj, M; Kulisevsky, J; Marin, C; Pérez, V; Rubio, A | 1 |
| Feinstein, DL; Galea, E; McGuire, S; Polak, PE; Sharp, A; Simonini, MV | 1 |
| Roczniak, W | 1 |
| Björklund, A; Carta, M; Devoto, P; Rogers, JT; Shin, E | 1 |
| Huang, C; Liu, J; Wang, HS; Wang, T; Wang, Y | 1 |
| Babuśka-Roczniak, M; Brodziak-Dopierała, B; Cipora, E; Kwapuliński, J; Nowak, P; Oświęcimska, JM; Roczniak, W; Widuchowski, W | 1 |
| Cao, LF; Chen, LH; Cheng, RX; Huang, Y; Liu, T; Luo, WF; Peng, XY; Wang, B; Zhou, FM | 1 |
1 review(s) available for dsp 4 and levodopa
| Article | Year |
|---|---|
[A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzylamines; Dopamine; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Norepinephrine; Parkinson Disease, Secondary; Pyridines | 1987 |
15 other study(ies) available for dsp 4 and levodopa
| Article | Year |
|---|---|
Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by L-dopa.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Benzylamines; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Nerve Endings; Neurotoxins; Norepinephrine | 1991 |
Increase in mouse brain regional noradrenaline turnover after L-dopa administration.
Topics: Animals; Benzylamines; Brain; Levodopa; Male; Mice; Mice, Inbred Strains; Norepinephrine | 1988 |
Pharmacological modifications of the neurotoxic action of the noradrenaline neurotoxin DSP4 on central noradrenaline neurons.
Topics: Amines; Animals; Benzylamines; Catecholamines; Central Nervous System; Desipramine; Female; In Vitro Techniques; Levodopa; Male; Neurons; Neurotransmitter Uptake Inhibitors; Norepinephrine; Pargyline; Rats; Rats, Inbred Strains; Synaptosomes | 1984 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal Ganglia; Behavior, Animal; Benzylamines; Brain Chemistry; Catalepsy; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Locus Coeruleus; Male; Motor Activity; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Statistics, Nonparametric; Tyrosine | 2004 |
Influence of noradrenaline denervation on MPTP-induced deficits in mice.
Topics: Animals; Auditory Pathways; Behavior, Animal; Benzylamines; Brain Chemistry; Denervation; Dopamine Agents; Hippocampus; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Neostriatum; Norepinephrine; Prefrontal Cortex; Substantia Nigra | 2006 |
Postnatal iron overload destroys NA-DA functional interactions.
Topics: Adrenergic Agents; Adrenergic alpha-Agonists; Animals; Animals, Newborn; Benzylamines; Clonidine; Corpus Striatum; Denervation; Dopamine; Dopamine Agents; Iron Overload; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Norepinephrine | 2007 |
Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Benzylamines; Brain; Caffeine; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Male; Motor Activity; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2007 |
Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benzylamines; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Levodopa; Male; Movement; Neurotoxins; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Recovery of Function; Synaptic Transmission; Time; Treatment Outcome | 2009 |
Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances.
Topics: Animals; Benzylamines; Cognition Disorders; Dyskinesia, Drug-Induced; Levodopa; Locus Coeruleus; Male; Maze Learning; Medial Forebrain Bundle; Memory, Short-Term; Motor Activity; Neurodegenerative Diseases; Oxidopamine; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Time Factors | 2009 |
Increasing CNS noradrenaline reduces EAE severity.
Topics: Adrenergic Uptake Inhibitors; Animals; Astrocytes; Atomoxetine Hydrochloride; Benserazide; Benzylamines; Brain Chemistry; Central Nervous System; Cytokines; Dopamine Agents; Encephalomyelitis, Autoimmune, Experimental; Female; Glial Fibrillary Acidic Protein; Immunohistochemistry; Levodopa; Mice; Mice, Inbred C57BL; Norepinephrine; Propylamines; T-Lymphocytes | 2010 |
Assessment of dopamine (DA) synthesis rate in selected parts of the rat brain with central noradrenergic lesion after administration of 5-HT3 receptor ligands.
Topics: Adrenergic Neurons; Animals; Benzylamines; Brain Injuries; Brain Stem; Carboxy-Lyases; Dopamine; Frontal Lobe; Hypothalamus; Levodopa; Male; Morphine; Ondansetron; Rats; Rats, Wistar; Receptors, Serotonin, 5-HT3; Thalamus | 2013 |
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benzylamines; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; Nerve Degeneration; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins, Type 1; Saporins; Stereotyped Behavior | 2014 |
L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzylamines; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Microdialysis; Neurotransmitter Agents; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine 3-Monooxygenase | 2014 |
The effect of central noradrenergic system lesion on dopamine (DA) and serotonin (5-HT) synthesis rate following administration of 5-HT3 receptor ligands in chosen parts of the rat brain.
Topics: Analgesics, Opioid; Animals; Autonomic Nervous System Diseases; Benzylamines; Biguanides; Brain Chemistry; Cerebellum; Dopamine; Hippocampus; Levodopa; Ligands; Male; Morphine; Neurotoxins; Ondansetron; Rats; Rats, Wistar; Serotonin; Serotonin 5-HT3 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists | 2015 |
Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease.
Topics: Animals; Benzylamines; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Norepinephrine; Oxidopamine; Pain; Parkinson Disease; Rats, Sprague-Dawley; Spinal Cord | 2016 |